Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3
Amy Wolfe,Georgia Stimpson,Danielle Ramsey,Giorgia Coratti,Sally Dunaway Young,Anna Mayhew,Marika Pane,Annemarie Rohwer,Robert Muni Lofra,Tina Duong,Emer O'Reilly,Evelin Milev,Matthew Civitello,Valeria A Sansone,Adele D'Amico,Enrico Bertini,Sonia Messina,Claudio Bruno,Emilio Albamonte,Elena Mazzone,Marion Main,Jacqueline Montes,Allan M Glanzman,Zarazuela Zolkipli-Cunningham,Amy Pasternak,Chiara Marini-Bettolo,John W Day,Basil T Darras,Darryl C De Vivo,Giovanni Baranello,Mariacristina Scoto,Richard S Finkel,Eugenio Mercuri,Francesco Muntoni,international SMA consortium (iSMAc)
DOI: https://doi.org/10.3233/JND-230211
Abstract:Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterised by progressive motor function decline. Motor function is assessed using several functional outcome measures including the Revised Hammersmith Scale (RHS). Objective: In this study, we present longitudinal trajectories for the RHS in an international cohort of 149 untreated paediatric SMA 2 and 3 patients (across 531 assessments collected between March 2015 and July 2019). Methods: We contextualise these trajectories using both the Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM). At baseline, this cohort included 50% females and 15% of patients had undergone spinal fusion surgery. Patient trajectories were modelled using a natural cubic spline with age, sex, and random effects for each patient. Results: RHS and HFMSE scores show similar trends over time in this cohort not receiving disease modifying therapies. The results confirm the strong correlation between the RHS and RULM previously observed in SMA types 2 and 3a. Scoliosis surgery is associated with a reduction of 3 points in the RHS, 4.5 points in the HFMSE for the SMA 2 population, and a reduction of 11.8 points in the RHS, and 13.4 points in the HFMSE for the SMA 3a populations. When comparing the RHS and RULM, there is a lower correlation in the type 3a's than the type 2 patients. In the SMA 2 population, there is no significant difference between the sexes in either the RHS or HFMSE trajectories. There is no significant difference in the RULM trajectory in the SMA 2 or 3a participants by sex. Conclusions: This study demonstrates that the RHS could be used in conjunction with other functional measures such as the RULM to holistically detect SMA disease progression. This will assist with fully understanding changes that occur with treatments, further defining trajectories and therapy outcomes.